Warning: Common Pain Relievers Unsafe for Heart Patients

Fortunately, there are alternatives for those needing daily pain relief.

The FDA mandated a cardiovascular safety trial of celecoxib (Celebrex). This trial, spearheaded by Dr. Nissen, compared moderate doses of celecoxib to ibuprofen and naproxenin 24,081 arthritis patients at increased cardiovascular risk needing daily pain relief. The cardiovascular risks from celecoxib were no greater than those conferred by the other NSAIDs.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access


Please enter your comment!
Please enter your name here